Avidity Biosciences (RNA) Preclinical Data Demonstrates DM1 Activity in Vitro and Durable Reduction in DMK Expression in NHPs in Vivo.
Go back to Avidity Biosciences (RNA) Preclinical Data Demonstrates DM1 Activity in Vitro and Durable Reduction in DMK Expression in NHPs in Vivo.| PROSENSA HOLD (NASDAQ: RNA) | Delayed: 12.17 -0.08 (0.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.25 | 52 Week High | $22.80 | |||
| Open | $12.27 | 52 Week Low | $4.12 | |||
| Day High | $12.39 | P/E | N/A | |||
| Day Low | $12.12 | EPS | $0.00 | |||
| Volume | 150,062 | |||||
